Join Now

Biolexis Therapeutics Initiates First-in-Human Clinical Trials for Novel, Oral Muscle-Sparing, Weight Loss and Type 2 Diabetes Therapies

By Press Release | Published October 9, 2025

Biolexis Therapeutics Initiates First-in-Human Clinical Trials for Novel, Oral Muscle-Sparing, Weight Loss and Type 2 Diabetes Therapies

Posted in BioUtah News | Tagged | Comments Off on Biolexis Therapeutics Initiates First-in-Human Clinical Trials for Novel, Oral Muscle-Sparing, Weight Loss and Type 2 Diabetes Therapies

Biolexis Therapeutics Advances Breakthrough GLP-1 and AMPK Programs into First-in-Human Clinical Trials

By Press Release | Published June 12, 2025

Groundbreaking Preclinical Data Propel Clinical Milestone

Posted in BioUtah News | Tagged | Comments Off on Biolexis Therapeutics Advances Breakthrough GLP-1 and AMPK Programs into First-in-Human Clinical Trials

Biolexis Therapeutics launches subsidiary Metabolexis to develop novel oral medicines for Obesity and Type 2 Diabetes to improve human longevity

By Press Release | Published November 30, 2023

Metabolexis focuses on GLP-1 weight loss and type 2 diabetic drug discoveries to improve accessibility and meet unprecedented demand.

Posted in BioUtah News | Tagged | Comments Off on Biolexis Therapeutics launches subsidiary Metabolexis to develop novel oral medicines for Obesity and Type 2 Diabetes to improve human longevity

Biolexis Secures $10 Million in Series A Funding to Advance Metabolic Drug Development

By Press Release | Published November 30, 2023

LED BY CLARKE CAPITAL, THE NEW FUNDING ROUND WILL ACCELERATE THE COMPANY’S DRUG DISCOVERY PIPELINE

Posted in BioUtah News | Tagged | Comments Off on Biolexis Secures $10 Million in Series A Funding to Advance Metabolic Drug Development

A Special Thanks To Our Elite Members